3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Carcinoma
1
Interventions
palbociclib
2
duvelisib
2
berzosertib
2
Fulvestrant
2
Everolimus
2
volagidemab
1
serabelisib
1
ribociclib
1
pembrolizumab
1
olaparib
1
obinutuzumab
1
lorlatinib
1
gedatolisib
1
encorafenib
1
cobimetinib
1
chiauranib
1
capivasertib
1
binimetinib
1
Topotecan
1
Radiotherapy
1
Panobinostat
1
PX-866
1
NVP-BKM120
1
Letrozole
1
Cetuximab
1
CYH33
1
BAY 1895344
1
AZD1390
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hereditary Sensory and Autonomic Neuropathies
×
PX-866
×
Clear all
NCT00726583
2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1
Completed
90 enrolled